Respiratory Distress Syndrome in Premature Infant Clinical Trial
— PROLISAOfficial title:
Respiratory Effect of the LISA (Less Invasive Surfactant Administration) Method With Sedation by Propofol Versus Absence of Sedation: Double-blind Comparative Randomized Clinical Trial.
The investigators propose to evaluate premedication with Propofol compared to a control strategy including a placebo with a possible rescue treatment with ketamine to ensure pain control before LISA Procedure . Investigators hypothesize that sedation with Propofol is safe and non-inferior to placebo for the risk of Mechanical Ventilation in the 72 hours following the procedure.
Status | Recruiting |
Enrollment | 542 |
Est. completion date | October 7, 2024 |
Est. primary completion date | October 7, 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | N/A and older |
Eligibility | Inclusion Criteria: - Preterm Infants < 32 wGA (weeks of gestational age) - Presenting a RDS (respiratory distress syndrome) - in the first 48 hours of life - treated by CPAP (continuous positive airway pressure) or BiPAP (Bilevel Positive Airway Pressure) - requiring surfactant : - FIO2 : (fraction of inspired oxygen) - if 28 - 31 SA : FiO2 =30% for a duration = 10mn - if <28 SA FIO2 =25% for a duration =10mn - SpO2 (arterial oxygen saturation) : to obtain a SpO2 between =88 and = 95% - Available IntraVenous line (peripheral, umbilical or central catheter) - Recipient of the French Social Security - Informed consent form signed Exclusion Criteria: - Congenital and/or major malformations - FIO2 >60% - Silverman score >6 - Contraindication to the use of Propofol : - Low Blood Pressure with 2 successive measurements (Mean < Gestational Age expressed in Weeks of Gestation) persisting after one volume expansion, - Use of inotropic medication to maintain a normal blood pressure. - Use of sedative or analgesic drugs (except paracetamol and ibuprofen) in the previous 24h - Coma, convulsions, areactivity at neurological examination |
Country | Name | City | State |
---|---|---|---|
France | Chu Amiens | Amiens | |
France | Chu Angers | Angers | |
France | Chu Brest | Brest | |
France | Chu Chambery | Chambéry | |
France | Chi Creteil | Créteil | |
France | CHU Grenoble Alpes | Grenoble | Isère |
France | Chu Limoges | Limoges | |
France | Ap-H Marseille | Marseille | |
France | Chu Nantes | Nantes | |
France | Chu Nimes | Nîmes | |
France | Chi Poissy St Germain | Poissy | |
France | Ch Rennes | Rennes | |
France | centre hospitalier deTroyes | Troyes | Aube |
Lead Sponsor | Collaborator |
---|---|
University Hospital, Grenoble |
France,
Berde CB, Walco GA, Krane EJ, Anand KJ, Aranda JV, Craig KD, Dampier CD, Finkel JC, Grabois M, Johnston C, Lantos J, Lebel A, Maxwell LG, McGrath P, Oberlander TF, Schanberg LE, Stevens B, Taddio A, von Baeyer CL, Yaster M, Zempsky WT. Pediatric analgesic — View Citation
Bourgoin L, Caeymaex L, Decobert F, Jung C, Danan C, Durrmeyer X. Administering atropine and ketamine before less invasive surfactant administration resulted in low pain scores in a prospective study of premature neonates. Acta Paediatr. 2018 Jul;107(7):1 — View Citation
Dargaville PA, Kamlin CO, De Paoli AG, Carlin JB, Orsini F, Soll RF, Davis PG. The OPTIMIST-A trial: evaluation of minimally-invasive surfactant therapy in preterm infants 25-28 weeks gestation. BMC Pediatr. 2014 Aug 27;14:213. doi: 10.1186/1471-2431-14-2 — View Citation
Dekker J, Lopriore E, Rijken M, Rijntjes-Jacobs E, Smits-Wintjens V, Te Pas A. Sedation during Minimal Invasive Surfactant Therapy in Preterm Infants. Neonatology. 2016;109(4):308-13. doi: 10.1159/000443823. Epub 2016 Feb 24. — View Citation
Dekker J, Lopriore E, van Zanten HA, Tan RNGB, Hooper SB, Te Pas AB. Sedation during minimal invasive surfactant therapy: a randomised controlled trial. Arch Dis Child Fetal Neonatal Ed. 2019 Jul;104(4):F378-F383. doi: 10.1136/archdischild-2018-315015. Ep — View Citation
Descamps CS, Chevallier M, Ego A, Pin I, Epiard C, Debillon T. Propofol for sedation during less invasive surfactant administration in preterm infants. Arch Dis Child Fetal Neonatal Ed. 2017 Sep;102(5):F465. doi: 10.1136/archdischild-2017-312791. Epub 201 — View Citation
Durrmeyer X, Daoud P, Decobert F, Boileau P, Renolleau S, Zana-Taieb E, Saizou C, Lapillonne A, Granier M, Durand P, Lenclen R, Coursol A, Nicloux M, de Saint Blanquat L, Shankland R, Boëlle PY, Carbajal R. Premedication for neonatal endotracheal intubati — View Citation
Ghanta S, Abdel-Latif ME, Lui K, Ravindranathan H, Awad J, Oei J. Propofol compared with the morphine, atropine, and suxamethonium regimen as induction agents for neonatal endotracheal intubation: a randomized, controlled trial. Pediatrics. 2007 Jun;119(6 — View Citation
Göpel W, Kribs A, Ziegler A, Laux R, Hoehn T, Wieg C, Siegel J, Avenarius S, von der Wense A, Vochem M, Groneck P, Weller U, Möller J, Härtel C, Haller S, Roth B, Herting E; German Neonatal Network. Avoidance of mechanical ventilation by surfactant treatm — View Citation
Kanmaz HG, Erdeve O, Canpolat FE, Mutlu B, Dilmen U. Surfactant administration via thin catheter during spontaneous breathing: randomized controlled trial. Pediatrics. 2013 Feb;131(2):e502-9. doi: 10.1542/peds.2012-0603. Epub 2013 Jan 28. — View Citation
Klotz D, Porcaro U, Fleck T, Fuchs H. European perspective on less invasive surfactant administration-a survey. Eur J Pediatr. 2017 Feb;176(2):147-154. doi: 10.1007/s00431-016-2812-9. Epub 2016 Dec 9. — View Citation
Owen LS, Manley BJ. Nasal intermittent positive pressure ventilation in preterm infants: Equipment, evidence, and synchronization. Semin Fetal Neonatal Med. 2016 Jun;21(3):146-53. doi: 10.1016/j.siny.2016.01.003. Epub 2016 Feb 26. Review. — View Citation
* Note: There are 12 references in all — Click here to view all references
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | need for mechanical ventilation after the procedure | Rate of mechanical ventilation from the start of the LISA procedure up to 72 hours of life. | 72hours | |
Secondary | Rate of MV (mechanical ventilation ) in each class of GA (<28, 28-31wGA) | Rate of MV (mechanical ventilation
) from the start of the LISA procedure up to 72 hours of life in each class of GA (<28, 28-31wGA) |
72hours | |
Secondary | FANS during LISA and 1h after LISA | Faceless acute neonatal pain scale (FANS) assessed during LISA and 1 hour after the procedure by an independent operator. | 1hour | |
Secondary | number of ketamine administrations for rescue | Number of ketamine administrations for rescue in order to obtain a FANS score <6 and to be able to proceed to LISA. | before LISA Procedure | |
Secondary | Number of laryngoscopies | Number of laryngoscopies needed to perform LISA | during LISA Procedure (T0) | |
Secondary | Tolerance and efficacy (Per procedure events): Apnea | Apnea requiring bag mask ventilation | during LISA Procedure (T0) | |
Secondary | Tolerance and efficacy (Per procedure events): emergency intubation | Emergency intubation after the drug injection before the LISA procedure can be performed or within 1h following the drug injection | from drug injection to 1hour after | |
Secondary | Tolerance and efficacy (Per procedure events): Viby Mogensen score | Clinician's satisfaction during laryngoscopy with the Viby Mogensen score :
Item Score 1 Score 2 Score 3 Score 4 Laryngoscopy Easy Fair Difficult Impossible Vocal cords Open Moving Closing Closed Coughing None Slight Moderate Severe Jaw relaxation Complete Slight Stiff Rigid Limb movements None Slight Moderate Severe the total score is calculated adding each item scores. min score = 5. max score = 20. An easy intubation would obtain a low score and a difficult intubation would have a high score. |
during LISA Procedure | |
Secondary | BPD (bronchopulmonary dysplasia) at 36 weeks of Gestational Age | Broncho Pulmonary Dysplasia at 36 weeks of Gestational Age | equivalent to 36 weeks of Gestational Age | |
Secondary | In-hospital morbidity and mortality: pneumothorax | Pneumothorax within 72hours | 72hours post LISA Procedure | |
Secondary | In-hospital morbidity and mortality: Necrotizing Enterocolitis | necrotizing enterocolitis during hospitalization | the day of discharge from hospital (the day depends to each participant : between 36-45 weeks of Gestational Age) | |
Secondary | In-hospital morbidity and mortality : sepsis | proven sepsis during hospitalization | the day of discharge from hospital (the day depends to each participant : between 36-45 weeks of Gestational Age) | |
Secondary | In-hospital morbidity and mortality: retinopathy | retinopathy of prematurity during hospitalization | the day of discharge from hospital (the day depends to each participant : between 36-45weeks of gestational ageGA) | |
Secondary | In-hospital morbidity and mortality | periventricular leukomalacia or grade 3 or 4 intraventricular hemorrhage during hospitalization | the day of discharge from hospital (the day depends to each participant : between 36-45weeks of Gestational Age) | |
Secondary | In-hospital morbidity and mortality: patent ductus arteriosus | treatment of a patent ductus arteriosus during hospitalization | the day of discharge from hospital (the day depends to each participant : between 36-45 weeks of Gestational Age) | |
Secondary | In-hospital morbidity and mortality: death 36weeks of Gestational Age | Death at 36 weeks of Gestational Age | equivalent to 36 weeks of Gestational Age | |
Secondary | In-hospital morbidity and mortality: death during hospitalization | in-hospital mortality | the day of discharge from hospital (the day depends to each participant : between 36-45weeks of Gestational Age) | |
Secondary | At two years of corrected age: ASQ (Ages and Stages Questionnaire) | ASQ (Ages and Stages Questionnaire) questionnaire is a general developmental screening tool (5 areas are evaluated: Communication, gross motor, fine motor, problem solving, and personal-social). Total score is the sum of each of the 5 area scores (wich are between 0-60. Total score is between 0 and 300. The higher the score is, the best developed the children is. | 2 years (corrected age) | |
Secondary | At two years of corrected age: motor function | Gross Motor Function Classification Scale (GMFCS) looks at movements such as sitting, walking and use of mobility devices. It is helpful because it provides families and clinicians with a clear description of a child's current motor function, and an idea of what equipment or mobility aids a child may need in the future, e.g. crutches, walking frames or wheelchairs.
Participant will be assignated to one of the 5 levels by the clinicians : a patient who is in level 5 has more motor impairments than a patient in level 1. |
2 years (corrected age) | |
Secondary | At two years of corrected age: vision | Visual functions : a clinical examination will conclude if the participant has a visual deficit or not. And in the deficit case, what kind of vision pathology. | 2 years (corrected age) | |
Secondary | At two years of corrected age: audition | Hearing functions : a clinical examination will conclude if the participant has a hearing deficit or not. And in the deficit case, what kind of audition pathology. | 2 years (corrected age) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Enrolling by invitation |
NCT04118400 -
Ventilator Weaning Outcome Between NIV-NAVA and Nasal CPAP (or IMV ) Modes in Premature Neonates
|
||
Completed |
NCT01941745 -
Efficacy of Recombinant Human Clara Cell 10 Protein (rhCC10) Administered to Premature Neonates With Respiratory Distress Syndrome
|
Phase 2 | |
Not yet recruiting |
NCT04019106 -
Budesonide With Intratracheal Surfactants in Extremely Preterm Infants
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT04862377 -
Intratracheal Budesonide With Surfactant to Prevent Bronchopulmmonary Dysplasia.
|
Phase 3 | |
Not yet recruiting |
NCT05791331 -
REspiratory MEchanics for Delivering Individualised Exogenous Surfactant
|
N/A | |
Completed |
NCT04086095 -
Feasibility Study - Neofact
|
N/A | |
Not yet recruiting |
NCT05609877 -
The NONA-LISA Trial
|
N/A | |
Recruiting |
NCT04326270 -
Crossover Comparison of Tidal Volume Delivery During Nasal Intermittent Positive Pressure Ventilation in Preterm Infants: Infant Cannula vs. Nasal Continuous Positive Airway Pressure Prongs
|
N/A | |
Active, not recruiting |
NCT03969992 -
A Dose-Ranging Study to Determine the Efficacy, Safety and Tolerability of AeroFact
|
Phase 2 | |
Completed |
NCT03700606 -
Physiological Changes With High-Flow Nasal Cannula
|
N/A | |
Recruiting |
NCT04359134 -
Combined Lung Ultrasounds and Transthoracic Electrical Bioimpedance in Preterm Infants With Respiratory Distress.
|
||
Not yet recruiting |
NCT06229821 -
Safety and Efficacy of Intrapulmonary Percussive Ventilation in Preterm Infants
|
N/A | |
Recruiting |
NCT05446389 -
PAL to Improve Oral Feeding for Infants With Chronic Lung Disease
|
N/A | |
Withdrawn |
NCT04914715 -
nHFOV Versus Invasive Conventional Ventilation for Preterm Neonates With Respiratory Distress Syndrome
|
N/A | |
Recruiting |
NCT03825835 -
30% or 60% Oxygen at Birth to Improve Neurodevelopmental Outcomes in Very Low Birthweight Infants
|
N/A | |
Recruiting |
NCT03562182 -
Effect of Steroid Administration on Maternal Blood Levels of hLPCAT1 mRNA
|
||
Completed |
NCT05031650 -
Open Lung Strategy During Non-Invasive Respiratory Support of Very Preterm Infants in the Delivery Room
|
N/A | |
Completed |
NCT03306524 -
The Role of Circuit Flow During Mechanical Ventilation of Neonates
|
N/A | |
Completed |
NCT01473264 -
Safety, Pk and Anti-inflammatory Effects of CC10 Protein in Premature Infants With Respiratory Distress Syndrome (RDS)
|
Phase 1/Phase 2 | |
Completed |
NCT03548324 -
Enteral Nutrition Tolerance And REspiratory Support (ENTARES)
|
N/A |